{
    "clinical_study": {
        "@rank": "87499", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine biomarkers of exposure to Harmful and Potentially\n      Harmful Constituents (HPHCs) in Cigarette Smoke and cardiovascular-related biomarkers in\n      smokers and non smokers."
        }, 
        "brief_title": "Determination of Biomarkers of Exposure and Biomarkers of Potential Harm in Asian Adult Cigarette Smokers", 
        "completion_date": {
            "#text": "February 2008", 
            "@type": "Actual"
        }, 
        "condition": [
            "Smoking", 
            "Healthy"
        ], 
        "condition_browse": {
            "mesh_term": "Smoking"
        }, 
        "detailed_description": {
            "textblock": "Since Japanese mortality associated with cardiovascular disease (CVD)  is lower than that in\n      the USA although Japan is one of the top four tobacco consuming countries, this study aims\n      to determine biomarkers of both level of exposure and CVD-related biological effects in\n      Japanese smokers compared to non-smokers.\n\n      Biomarkers of Exposure (BoExp) include 2-naphthylamine (2-NA), 4-aminobiphenyl (4-ABP),\n      4-(methylnitrosaminoi)-1-(3-pyridil)-1-butanone (NNK), carbon monoxide (CO), nicotine,\n      pyrene and 0-toluidine (o-TOL). CVD-related biomarkers include white blood cell (WBC) count,\n      high sensitivity C-reactive protein (hs-CRP) and homocysteine in plasma; complemented with\n      urinary 8-epi-prostaglandin F2\u03b1 (8-epi-PGF2\u03b1), plasma malondialdehyde (MDA), urinary\n      11-DTXB2, plasma fibrinogen, high-density lipoprotein-cholesterol, triglycerides, sICAM-1,\n      sVCAM-1 and von Willebrand Factor."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Smokers have smoked commercially available conventional cigarettes (CC)\n\n          -  With a minimum consumption of 10 CC per day for the last 5 years\n\n        Exclusion Criteria:\n\n          -  Any prior medical condition or chronic disease\n\n          -  Recent infection\n\n          -  History of cancer\n\n          -  Use of concomitant medication\n\n          -  History of alcohol abuse\n\n          -  Pregnant women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "30 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Healthy male and female Japanese smokers and non smokers, 30 years of age or older."
            }
        }, 
        "enrollment": {
            "#text": "1069", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02103751", 
            "org_study_id": "CS06-01"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "biomarkers", 
            "HPHCs", 
            "CVD", 
            "smoking", 
            "Smokers", 
            "non-smokers"
        ], 
        "lastchanged_date": "April 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan"
                }, 
                "name": "Bio-Iatric Centre, Research Institute for Clinical Pharmacology, Kitasato University"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Multi-center Study to Determine the Levels of Biomarkers of Potential Harm and Biomarkers of Exposure to Cigarette Smoke in Asian Adult Smokers and Non-smokers", 
        "overall_official": {
            "affiliation": "Kitasato University, Tokyo, Japan", 
            "last_name": "Prof. Tomoko Hasunuma, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Institutional Review Board of Medical Co. LTA", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2007", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "To measure the level of smoking, at baseline the Fagerstrom nicotine dependence test and urinary cotinine are measured. For measurement of biomarkers of exposure, blood and 24 hour urine sampling are performed at V2.", 
                "measure": "The level of biomarkers of Exposure (BoExp) to HPHCs - present in cigarette smoke -  in Asian smokers compared to non smokers", 
                "safety_issue": "Yes", 
                "time_frame": "At Visit 2 (in between 3 and 14 days after Visit 1)"
            }, 
            {
                "measure": "The level of CVD-related biomarkers in Asian smokers compared to non smokers", 
                "safety_issue": "Yes", 
                "time_frame": "At Visit 2 (in between 3 and 14 days after Visit 1)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02103751"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Philip Morris Products S.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Philip Morris Products S.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2007", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}